OSE Immunotherapeutics Announces Publication of Peer-Reviewed Data on CLEC-1, its Novel Myeloid Immune Checkpoint in 'Science Advances'

Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced the publication of data in the peer-reviewed journal Science Advances on a first-in-classpreclinical

Related Keywords

Paris ,France General ,France ,French ,Sabrina Pengam ,Debajyoti Sinha ,Cedric Louvet ,Isabelle Girault ,Vanessa Gauttier ,Maria Dolores Lopez ,Javier Saenz ,Nicolas Poirier ,Virginie Thepenier ,Emmanuelle Wilhelm ,Thomas Guillot ,Caroline Mary ,Camille Ligeron ,Emmanuel Merieau ,Ariane Desselle ,Elise Chiffoleau ,Marion Drouin ,Cynthia Fourgeux ,Sylvie Berrebi David ,Florence Portejoie ,Nantes University Hospital ,Translational Research In Transplantation ,Linkedin ,Nantes University At Hospital ,Twitter ,Boehringer Ingelheim ,International Media ,Veloxis Pharmaceuticals Inc ,Regulatory News ,Science Advances ,Translational Research ,Chief Executive Officer ,C Type Lectin ,Myeloid Derived Suppressor Cells ,Translational Immunology ,Nantes University ,Non Small Cell Lung Cancer ,Veloxis Pharmaceuticals ,Universal Registration Document ,Berrebi David Dible Eleanor Perkin ,Immunotherapeutics ,Nnounces ,Publication ,Beer ,Eviewed ,Data ,Alec ,Novel ,Amyeloid ,Immune ,Checkpoint ,Science ,Advances ,